Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Primary Mediastinal B-Cell Lymphoma”

152 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 152 results

Early research (Phase 1)Study completedNCT02924402
What this trial is testing

Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

Who this might be right for
B-cell Non-Hodgkins LymphomaChronic Lymphocytic Leukemia
Xencor, Inc. 154
Testing effectiveness (Phase 2)Active Not RecruitingNCT06504394
What this trial is testing

Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)

Who this might be right for
Classical Hodgkin Lymphoma RecurrentClassical Hodgkin Lymphoma RefractoryPrimary Mediastinal Large B-cell Lymphoma Recurrent+1 more
Merck Sharp & Dohme LLC
Early research (Phase 1)Active Not RecruitingNCT04007029
What this trial is testing

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Who this might be right for
CD19 PositiveCD20 PositiveRecurrent Chronic Lymphocytic Leukemia+11 more
Jonsson Comprehensive Cancer Center 24
Early research (Phase 1)Ended earlyNCT04187872
What this trial is testing

LITT and Pembrolizumab in Recurrent Brain Metastasis

Who this might be right for
MelanomaNon-small Cell Lung Carcinoma (NSCLC)Renal Cell Carcinoma (RCC)+12 more
University of Florida 10
Testing effectiveness (Phase 2)Looking for participantsNCT07097363
What this trial is testing

Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma

Who this might be right for
B-Cell Non-Hodgkin LymphomaBurkitt LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise Specified+6 more
University of Washington 18
Not applicableStudy completedNCT05130489
What this trial is testing

CAR T Cell Therapy Related Cardiovascular Outcomes

Who this might be right for
Cardiovascular DiseasesB-cell Acute Lymphoblastic LeukemiaB-cell Lymphoma Refractory+5 more
University College London Hospitals 150
Testing effectiveness (Phase 2)Looking for participantsNCT06238648
What this trial is testing

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

Who this might be right for
Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedPrimary Mediastinal Large B-Cell LymphomaTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Academic and Community Cancer Research United 120
Not applicableLooking for participantsNCT06796517
What this trial is testing

Immunotherapy in Lymphoma

Who this might be right for
Relapsed/refractory High Grade B Cell LymphomaHigh Grade B-cell LymphomaDiffuse Large B Cell Lymphoma Relapsed+2 more
Sung-Soo Park 72
Testing effectiveness (Phase 2)Active Not RecruitingNCT03038672
What this trial is testing

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Who this might be right for
ALK-Positive Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma Activated B-Cell TypeDiffuse Large B-Cell Lymphoma Associated With Chronic Inflammation+32 more
National Cancer Institute (NCI) 54
Testing effectiveness (Phase 2)Study completedNCT02142049
What this trial is testing

Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Who this might be right for
Diffuse Large B Cell Lymphoma RelapsedDiffuse Large B Cell Lymphoma Refractory
Pharmacyclics LLC. 35
Testing effectiveness (Phase 2)Active Not RecruitingNCT04787263
What this trial is testing

CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML

Who this might be right for
Acute Lymphoblastic LeukemiaDiffuse Large B Cell LymphomaPrimary Mediastinal Lymphoma
Bambino Gesù Hospital and Research Institute 32
Early research (Phase 1)Looking for participantsNCT06703892
What this trial is testing

Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies

Who this might be right for
Diffuse Large B Cell Lymphoma RelapsedDiffuse Large B Cell Lymphoma RefractoryFollicular Lymphoma ( FL)+3 more
GenomeFrontier Therapeutics TW Co., Ltd. 18
Testing effectiveness (Phase 2)Looking for participantsNCT06550141
What this trial is testing

Emapalumab Prevention of CAR-T Cell Associated Toxicities

Who this might be right for
Large B-cell LymphomaRelapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma+4 more
Marcela V. Maus, M.D.,Ph.D. 28
Early research (Phase 1)Looking for participantsNCT04231877
What this trial is testing

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma

Who this might be right for
Aggressive Non-Hodgkin LymphomaALK-Positive Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise Specified+6 more
University of Washington 56
Testing effectiveness (Phase 2)Study completedNCT01516567
What this trial is testing

Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation

Who this might be right for
Primary Mediastinal Large B Cell Lymphoma
Gustave Roussy, Cancer Campus, Grand Paris 47
Not applicableLooking for participantsNCT05377307
What this trial is testing

Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy

Who this might be right for
Diffuse Large B Cell LymphomaLarge B-cell LymphomaPrimary Mediastinal Large B Cell Lymphoma+2 more
Pell Bio-Med Technology Co., Ltd. 49
Testing effectiveness (Phase 2)Study completedNCT03484819
What this trial is testing

Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRecurrent Primary Mediastinal Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma+1 more
National Cancer Institute (NCI) 12
Testing effectiveness (Phase 2)Looking for participantsNCT07283822
What this trial is testing

Amping up With PemJAK

Who this might be right for
Non-Hodgkin LymphomaHodgkin Disease LymphomaNon-Hodgkin Lymphoma Refractory/ Relapsed+5 more
Seda S. Tolu 53
Testing effectiveness (Phase 2)Active Not RecruitingNCT05507541
What this trial is testing

TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Recurrent ALK Positive Large B-Cell LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation+25 more
Mayo Clinic 10
Testing effectiveness (Phase 2)Ended earlyNCT04205838
What this trial is testing

Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell LymphomaProgressive Disease+8 more
Jonsson Comprehensive Cancer Center 23
Load More Results
66